Atara 
Welcome,         Profile    Billing    Logout  
 6 Products   0 Diseases  6 Products   8 Trials   331 News 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ATA2271 / Memorial Sloan-Kettering Cancer Center
NCT04577326: Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

Active, not recruiting
1
14
US
cyclophosphamide, CAR T cells
Memorial Sloan Kettering Cancer Center, Atara Biotherapeutics
Malignant Pleural Mesothelioma (MPM)
09/25
09/25
NCT06623396: A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

Recruiting
1
18
US
M28z1XXPD1DNR CAR
Memorial Sloan Kettering Cancer Center
Mesothelin Positive, Mesothelin-Expressing Tumors, Esophageal Adenocarcinoma, Esophageal Adenocarcinomas, Esophagogastric Adenocarcinoma, Peritoneal Carcinomatosis, Breast Neoplasms, Diabetes Mellitus
09/28
09/28
ATA520 / Atara
NCT01758328: Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

Completed
1
29
US
busulfan, melphalan, fludarabine, anti-thymocyte globulin (ATG), a T cell depleted stem cell transplant
Memorial Sloan Kettering Cancer Center
Multiple Myeloma
03/25
03/25
Tab-cel (tabelecleucel) / Atara
ALLELE, NCT03394365 / 2017-002949-30: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

Checkmark Data from ALLELE trial for post-transplant lymphoproliferative disease
Dec 2021 - Dec 2021: Data from ALLELE trial for post-transplant lymphoproliferative disease
Recruiting
3
66
Europe, Canada, US, RoW
tabelecleucel, tab-cel®, ATA129, EBV-CTL
Pierre Fabre Medicament
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
08/25
06/27
EBVision, NCT04554914 / 2020-000177-25: A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases

Hourglass Jan 2023 - Dec 2023 : From P2 trial for Epstein-Barr virus-associated sarcoma
Recruiting
2
190
Europe, US
Tabelecleucel, tab-cel®, ATA129, EBV-CTLs
Atara Biotherapeutics
Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma
06/27
05/29
NCT02822495: Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

No Longer Available
N/A
NA
tabelecleucel, tab-cel®, ATA129, EBV-CTL
Atara Biotherapeutics
Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Epstein-Barr Viremia, Lymphoma, AIDS-related, Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Primary Immunodeficiency (PID), Leiomyosarcoma (LMS), Nasopharyngeal Carcinoma (NPC), Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Acquired Immunodeficiency (AID), Solid Organ Transplant Complications, Stem Cell Transplant Complications
 
 
ATA188 / Atara
EMBOLD, NCT03283826: Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

Terminated
1/2
134
Canada, US, RoW
ATA188, Epstein-Barr Virus-directed cytotoxic T lymphocytes (CTLs), EBV-CTLs, EBV-targeted T-cell, Placebo
Atara Biotherapeutics
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
11/23
01/24
ATA3219 / Atara
ATA3219-NHL-103, NCT06256484: A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Terminated
1
1
US, RoW
ATA3219
Atara Biotherapeutics
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
03/25
03/25
ATA3219-AEC-104, NCT06429800: A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

Withdrawn
1
52
US
ATA3219
Atara Biotherapeutics
Lupus Nephritis, Systemic Lupus Erythematosus
04/25
04/25
adimlecleucel (ATA230) / Atara
NCT02136797: Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

Completed
2
77
US
CMVpp65 Specific T-cells
Memorial Sloan Kettering Cancer Center
CMV Infection, Persistent CMV Viremia
02/24
02/24
NCT03010332: Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease

No Longer Available
N/A
NA
Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs), ATA230
Atara Biotherapeutics
CMV Viremia, CMV Disease
 
 
ATA621 / Atara
No trials found
ATA368 / Atara
No trials found
ATA3271 / Atara
No trials found
Undisclosed CAR-T cell therapy / Atara, Memorial Sloan-Kettering Cancer Center
No trials found
ATA3431 / Atara, H. Lee Moffitt Cancer Center and Research Institute
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ATA2271 / Memorial Sloan-Kettering Cancer Center
NCT04577326: Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

Active, not recruiting
1
14
US
cyclophosphamide, CAR T cells
Memorial Sloan Kettering Cancer Center, Atara Biotherapeutics
Malignant Pleural Mesothelioma (MPM)
09/25
09/25
NCT06623396: A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

Recruiting
1
18
US
M28z1XXPD1DNR CAR
Memorial Sloan Kettering Cancer Center
Mesothelin Positive, Mesothelin-Expressing Tumors, Esophageal Adenocarcinoma, Esophageal Adenocarcinomas, Esophagogastric Adenocarcinoma, Peritoneal Carcinomatosis, Breast Neoplasms, Diabetes Mellitus
09/28
09/28
ATA520 / Atara
NCT01758328: Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

Completed
1
29
US
busulfan, melphalan, fludarabine, anti-thymocyte globulin (ATG), a T cell depleted stem cell transplant
Memorial Sloan Kettering Cancer Center
Multiple Myeloma
03/25
03/25
Tab-cel (tabelecleucel) / Atara
ALLELE, NCT03394365 / 2017-002949-30: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

Checkmark Data from ALLELE trial for post-transplant lymphoproliferative disease
Dec 2021 - Dec 2021: Data from ALLELE trial for post-transplant lymphoproliferative disease
Recruiting
3
66
Europe, Canada, US, RoW
tabelecleucel, tab-cel®, ATA129, EBV-CTL
Pierre Fabre Medicament
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
08/25
06/27
EBVision, NCT04554914 / 2020-000177-25: A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases

Hourglass Jan 2023 - Dec 2023 : From P2 trial for Epstein-Barr virus-associated sarcoma
Recruiting
2
190
Europe, US
Tabelecleucel, tab-cel®, ATA129, EBV-CTLs
Atara Biotherapeutics
Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma
06/27
05/29
NCT02822495: Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

No Longer Available
N/A
NA
tabelecleucel, tab-cel®, ATA129, EBV-CTL
Atara Biotherapeutics
Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Epstein-Barr Viremia, Lymphoma, AIDS-related, Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Primary Immunodeficiency (PID), Leiomyosarcoma (LMS), Nasopharyngeal Carcinoma (NPC), Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Acquired Immunodeficiency (AID), Solid Organ Transplant Complications, Stem Cell Transplant Complications
 
 
ATA188 / Atara
EMBOLD, NCT03283826: Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

Terminated
1/2
134
Canada, US, RoW
ATA188, Epstein-Barr Virus-directed cytotoxic T lymphocytes (CTLs), EBV-CTLs, EBV-targeted T-cell, Placebo
Atara Biotherapeutics
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
11/23
01/24
ATA3219 / Atara
ATA3219-NHL-103, NCT06256484: A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Terminated
1
1
US, RoW
ATA3219
Atara Biotherapeutics
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
03/25
03/25
ATA3219-AEC-104, NCT06429800: A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

Withdrawn
1
52
US
ATA3219
Atara Biotherapeutics
Lupus Nephritis, Systemic Lupus Erythematosus
04/25
04/25
adimlecleucel (ATA230) / Atara
NCT02136797: Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

Completed
2
77
US
CMVpp65 Specific T-cells
Memorial Sloan Kettering Cancer Center
CMV Infection, Persistent CMV Viremia
02/24
02/24
NCT03010332: Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease

No Longer Available
N/A
NA
Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs), ATA230
Atara Biotherapeutics
CMV Viremia, CMV Disease
 
 
ATA621 / Atara
No trials found
ATA368 / Atara
No trials found
ATA3271 / Atara
No trials found
Undisclosed CAR-T cell therapy / Atara, Memorial Sloan-Kettering Cancer Center
No trials found
ATA3431 / Atara, H. Lee Moffitt Cancer Center and Research Institute
No trials found

Download Options